Flexion Therapeutics And Xenon Pharmaceuticals Announce Flexion's Acquisition Of An Investigational NaV1.7 Inhibitor For The Treatment Of Post-Operative Pain; Xenon Received $3M Upfront And Is Eligible For Additional Milestones
Benzinga Newsdesk